Sunshine Biopharma Inc. Deferred Foreign Income Tax Expense (Benefit)
Sunshine Biopharma Inc. (SBFM) reported Deferred Foreign Income Tax Expense (Benefit) of $94.94 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-04-03
- Sunshine Biopharma Inc. deferred foreign income tax expense (benefit) for fiscal 2025 was $94.94K.
- Sunshine Biopharma Inc. deferred foreign income tax expense (benefit) for fiscal 2024 was -$144.47K, a 1010.36% decline from fiscal 2023.
- Sunshine Biopharma Inc. deferred foreign income tax expense (benefit) for fiscal 2023 was $15.87K, a 337.43% increase from fiscal 2022.
- Sunshine Biopharma Inc. deferred foreign income tax expense (benefit) for fiscal 2022 was $3.63K.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $94.94K 10-K · filed 2026-04-03 |
| 2024-12-31 | -$144.47K 10-K · filed 2026-04-03 |
| 2023-12-31 | $15.87K 10-K · filed 2024-03-28 |
| 2022-12-31 | $3.63K 10-K · filed 2023-04-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |